CH BIOTECH SER (08037) has announced an expectation that the group will record a net loss of no more than HK$100 million for the year ending December 31, 2025. This represents a decrease of approximately 60% compared to the net loss of HK$252 million reported for the year ending December 31, 2024.

The significant improvement anticipated for the 2025 fiscal year is primarily attributed to several factors. These include (i) insurance compensation income of approximately HK$14 million received in the 2025 fiscal year for damages caused by heavy rain to a construction site in Hainan during the 2024 fiscal year; (ii) a reduction in research and development costs within the immunotherapy segment; (iii) the successful implementation of cost-control measures leading to lower administrative expenses; and (iv) a one-time impairment loss on property, plant, equipment, and intangible assets that was recognized in the 2024 fiscal year.